Results 101 to 110 of about 2,552 (169)

Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration. [PDF]

NPJ Prim Care Respir Med
Wang Z, Zhou Y, Guan WJ, Lin J, Cai G, Zheng J, Wu F, Deng Z, Zhong NS, Ran P.   +9 more
europepmc   +1 more source

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD. [PDF]

ERJ Open Res
Kayser T, Struß N, Pflock R, Heusser K, Kern AL, Voskrebenzev A, Behrendt L, Kaireit TF, Badorrek P, Tank J, Andreas S, Jordan J, Vogel-Claussen J, Hohlfeld JM.   +13 more
europepmc   +1 more source

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Thorac Dis
Gao S, Zhuang W, Song Q, Yan D, Chen L, Lai Z, Cheng Y, Yang X, Hu S.   +8 more
europepmc   +1 more source

Comparative In Vitro Deposition Analysis of Formoterol, Glycopyrronium, and Tiotropium Delivered via Capsule-Based DPI. [PDF]

Pharmaceutics
Sikora A, Chałupka J, Lewandowska K, Drapińska P, Marszałł MP.   +4 more
europepmc   +1 more source

New drugs: Tiotropium bromide

Australian Prescriber, 2003
openaire   +1 more source

Analysis of Current Status and Influencing Factors of Inhaler Treatment Adherence Among COPD Patients. [PDF]

Int J Chron Obstruct Pulmon Dis
Jin Z, Ba B, Zhang W, Yang Z, Wang X.
europepmc   +1 more source

Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Cardiovasc Med
Lan Y, Hu D, Huang S, Xu M, He Q.
europepmc   +1 more source

Lower baseline FEV1 is associated with greater FEV1 improvement after tiotropium add-on in uncontrolled asthma. [PDF]

Medicine (Baltimore)
Shim JS, Ahn KM, Kim MH, Cho YJ.
europepmc   +1 more source